Sensyne Health plc announces the appointment of Dr David Ruau to the newly created role of Chief Scientific Officer with effect from 01 September 2021. In this role, David will lead the research effort at Sensyne aimed at applying ethical AI to the improvement of patient care and the discovery and development of new medicines. Dr David Ruau is an experienced leader in the application of Big Data and AI to pharmaceutical research & development and joins Sensyne from Bayer where, from 2017, he was Head of Global Data Assets and Decision Science.